Evidence map›Paper›PMID 38776716›Full record

ReviewCurrent opinion in immunology2024

Yin and yang of interferons: lessons from the coronavirus disease 2019 (COVID-19) pandemic.

Sara Svensson Akusjärvi, Ivan Zanoni

Abstract readReview
In one paragraph

Review in Current opinion in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Unique nasal cell states induced by common pediatric respiratory viruses.bioRxiv : the preprint server for biology · 2026
    Article
  3. Review
  4. Review
  5. Kids' noses resist COVID-19.The Journal of experimental medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sara Svensson AkusjärviHarvard Medical School, Division of Immunology, Boston Children's Hospital, Boston, MA, USA; Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Ivan ZanoniHarvard Medical School, Division of Immunology, Boston Children's Hospital, Boston, MA, USA; Division of Gastroenterology, Boston Children's Hospital, Boston, MA, USA. Electronic address: ivan.zanoni@childrens.harvard.edu.

Funding

Type III interferon Control of Mucosal ImmunityR01DK115217 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI Scott B Snapper, Ivan Zanoni · 2017 to 2026
$5.6M
Innate control of the inflammatory process during fungal infectionsR01AI121066 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI ZANONI, IVAN · 2016 to 2025
$4.8M
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannansR01AI165505 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Ivan Zanoni · 2021 to 2026
$4.6M
Macrophage immunometabolism controls septic shockR01AI170632 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Ivan Zanoni · 2023 to 2026
$2.5M
NIAID NIH HHS R01 AI121066NIAID NIH HHS R01 AI165505NIAID NIH HHS R01 AI170632NIDDK NIH HHS R01 DK115217
6 · The paper itself

Abstract

The host immune response against severe acute respiratory syndrome coronavirus 2 includes the induction of a group of natural antiviral cytokines called interferons (IFNs). Although originally recognized for their ability to potently counteract infections, the mechanistic functions of IFNs in patients with varying severities of coronavirus disease 2019 (COVID-19) have highlighted a more complex scenario. Cellular and molecular analyses have revealed that timing, location, and subtypes of IFNs produced during severe acute respiratory syndrome coronavirus 2 infection play a major role in determining disease progression and severity. In this review, we summarize what the COVID-19 pandemic has taught us about the protective and detrimental roles of IFNs during the inflammatory response elicited against a new respiratory virus across different ages and its longitudinal consequences in driving the development of long COVID-19.

Indexed as

COVID-19InterferonsSARS-CoV-2AnimalsHumansPandemicsYin-YangInterferons

Identifiers

PMID38776716
PMCPMC11162909

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.